Drug maker GlaxoSmithKline today warned of job losses as it announced cost-cutting plans to offset falling sales of diabetes treatment Avandia.
The group, which was rocked earlier this year by health scares surrounding Avandia, confirmed it would need to axe jobs as part of a drive to save up to £700m (€1bn) in annual costs within three years.
Less than three months ago rival pharmaceutical giant AstraZeneca announced a similar three-year cost cutting plan, which would see the loss of 7,600 jobs worldwide.
GSK today said it would shut down a number of manufacturing sites under its savings strategy.
The group, which employs more than 100,000 people worldwide, has manufacturing operations across the UK, including sites at Ware, Temple Hill in Dartford, Maidenhead and Worthing.